Yilmaz, HalimKocabas, HilalErkin, Gulten2024-02-232024-02-2320130303-464Xhttps://hdl.handle.net/20.500.12452/17602Secondary amyloidosis (type AA) is rarely encountered but can be a significant complication of ankylosing spondylitis (AS) and may lead to proteinuria and renal dysfunction. Anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents may be used to induce clinical remission by suppressing systemic inflammation in secondary amyloidosis. The patient described, with the diagnosis of AS, was diagnosed with secondary amyloidosis, despite treatment with disease modifying anti-rheumatic medication. He developed marked proteinuria, renal dysfunction and low levels of serum albumin. Diagnosis of amyloidosis was confirmed by renal biopsy During a 2-year treatment period with etanercept, an anti-TNF-alpha agent, a definite improvement was determined in all parameters. This case illustrates that in the treatment of secondary amyloidosis related to AS, etanercept, an anti-TNF-alpha agent, can be considered an effective therapeutic option.eninfo:eu-repo/semantics/closedAccessAnkylosing SpondylitisSecondary AmyloidosisEtanerceptRenal FunctionArticle384299301244350362-s2.0-84893463170Q3WOS:000330915500011Q4